<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04279613</url>
  </required_header>
  <id_info>
    <org_study_id>TN27 Immunoplasmid Therapy</org_study_id>
    <secondary_id>UC4DK117009</secondary_id>
    <nct_id>NCT04279613</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041</brief_title>
  <acronym>TOPPLE T1D</acronym>
  <official_title>A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Administered Subcutaneously to Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a placebo-controlled, double-blinded within cohorts, randomized, multiple&#xD;
      ascending dose trial with a sequential trial design. The primary outcome is to investigate&#xD;
      the safety and tolerability of ascending subcutaneous weekly doses of NNC0361-0041 plasmid in&#xD;
      patients with T1D.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 48 patients with T1D are planned to be studied in 4 cohorts of 12 patients (9 on&#xD;
      active and 3 on placebo treatment). Within each cohort, sentinel enrollment will occur and&#xD;
      safety assessment will occur before remaining participants are enrolled. The treatment period&#xD;
      will be 12 weeks with once weekly dosing leading to 12 doses in total. Dose escalation will&#xD;
      occur after data safety review (as described in section 4.9.2). An MMTT to assess insulin&#xD;
      secretion will be done at baseline, 1, 3, 6, and 12 months. The follow-up (FU) period will be&#xD;
      1 week after the last dose, as well as 4, 6 and 12 months after the first dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">July 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The trial is a placebo-controlled, double-blinded within cohorts, randomized, multiple ascending dose trial with a sequential trial design. A total of 48 patients with T1D are planned to be studied in 4 cohorts of 12 patients (9 on active and 3 on placebo treatment).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Number of adverse events recorded from the time of first dosing (Day 1) and until completion of the follow-up visit #17</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the area under the plasma C-peptide concentration-time curve</measure>
    <time_frame>3 months</time_frame>
    <description>Relative change in the area under the plasma C-peptide concentration-time curve from time 0 to 2 hours during MMTT from baseline to 3 months between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Type I Diabetes</condition>
  <arm_group>
    <arm_group_label>NNC0361-0041</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: 9 mg/ml Solution for injection Route of administration: Subcutaneous Initial dose/Unit dose strength(s)/Dosage level(s) in cohort 1: 1mg Additional doses in cohorts 2, 3, and 4: 5mg, 12.5mg and 25mg Dosing instructions: Once weekly on site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage form: Solution for injection Route of administration: Subcutaneous Dosing instructions: Once weekly on site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0361-0041</intervention_name>
    <description>Recombinant supercoiled plasmid encoding four human proteins: (pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2) is administered s.c. via syringe and needle.</description>
    <arm_group_label>NNC0361-0041</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing to provide Informed Consent&#xD;
&#xD;
          2. Participants must live in a location with rapid access to emergency medical services&#xD;
&#xD;
          3. Age 18-45 years (both inclusive) at the time of signing informed consent&#xD;
&#xD;
          4. Must have a diagnosis of T1D for less than 48 months at randomization&#xD;
&#xD;
          5. Must have at least one diabetes-related autoantibody present (GAD65A; mIAA, if&#xD;
             obtained within 10 days of the onset of insulin therapy; IA-2A; ICA; or ZnT8A)&#xD;
&#xD;
          6. Must have stimulated C-peptide levels greater than or equal to 0.2 pmol/ml measured&#xD;
             during an MMTT conducted at least 21 days from diagnosis of diabetes and within one&#xD;
             month (37 days) of randomization&#xD;
&#xD;
          7. Be willing to comply with intensive diabetes management&#xD;
&#xD;
          8. HbA1c ≤8.5% at screening&#xD;
&#xD;
          9. Subjects who are CMV and/or EBV seronegative at screening must be CMV and/or EBV PCR&#xD;
             negative within 30 days of randomization and may not have had signs or symptoms of a&#xD;
             CMV and/or EBV compatible illness lasting longer than 7 days within 30 days of&#xD;
             randomization&#xD;
&#xD;
         10. Be up to date on recommended immunizations&#xD;
&#xD;
         11. Be at least 6 weeks from last live immunization&#xD;
&#xD;
         12. Be at least 4 weeks from killed vaccine other than flu vaccine&#xD;
&#xD;
         13. Participants are required to receive killed influenza vaccination at least 2 weeks&#xD;
             prior to randomization when vaccine for the current or upcoming flu season is&#xD;
             available&#xD;
&#xD;
         14. Be willing and medically acceptable to postpone live vaccines during the treatment&#xD;
             period and for 3 months following last dose of study drug&#xD;
&#xD;
         15. If participant is female with reproductive potential, she must have a negative&#xD;
             pregnancy test at screening and be willing to avoid pregnancy using a highly effective&#xD;
             contraceptive method for the 12 months of the study&#xD;
&#xD;
         16. Males of reproductive age must use adequate contraceptive method during the treatment&#xD;
             phase and for 3 months following last dose of study drug&#xD;
&#xD;
         17. Be at least 2 weeks from receiving a single dose COVID-19 vaccine or at least 2 weeks&#xD;
             from completing a multi-dose COVID-19 vaccine series at the time of receiving study&#xD;
             drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Potential participants must not meet any of the following exclusion criteria:&#xD;
&#xD;
          1. One or more screening laboratory values as stated&#xD;
&#xD;
               1. Leukocytes &lt; 3,000/μL&#xD;
&#xD;
               2. Neutrophils &lt;1,500 /μL&#xD;
&#xD;
               3. Lymphocytes &lt;800 /μL&#xD;
&#xD;
               4. Platelets &lt;100,000 /μL&#xD;
&#xD;
               5. Haemoglobin &lt;6.2 mmol/L (10.0 g/dL)&#xD;
&#xD;
               6. Potassium &gt;5.5 mmol/L or &lt;3.0 mmol/L&#xD;
&#xD;
               7. Sodium &gt;150mmol/L or &lt; 130mmol/L&#xD;
&#xD;
               8. AST or ALT ≥2.5 times the upper limits of normal&#xD;
&#xD;
               9. Bilirubin ≥ 1.5 times upper limit of normal&#xD;
&#xD;
              10. Glomerular Filtration Rate (eGFR) value of eGFR &lt; 60 ml/min/1.73 m2 as defined by&#xD;
                  KDIGO 2012 (43)&#xD;
&#xD;
              11. Any other laboratory abnormality that might, in the judgment of the investigator,&#xD;
                  place the subject at unacceptable risk for participation in this trial&#xD;
&#xD;
          2. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control&#xD;
             within prior 7 days of screening&#xD;
&#xD;
          3. Use of other immunosuppressive agents including chronic use of systemic steroids.&#xD;
             Topical products are acceptable (nasal, conjunctival, skin)&#xD;
&#xD;
          4. Have active signs or symptoms of acute infection at the time of randomization&#xD;
&#xD;
          5. Have current, confirmed COVID-19 infection&#xD;
&#xD;
          6. Chronic active infection other than localized skin infections&#xD;
&#xD;
          7. Have evidence of prior or current tuberculosis infection as assessed by PPD,&#xD;
             interferon gamma release assay or by history&#xD;
&#xD;
          8. Have evidence of current or past HIV, Hepatitis B infection&#xD;
&#xD;
          9. Have evidence of active Hepatitis C infection&#xD;
&#xD;
         10. Vaccination with a live virus within the last 6 weeks and killed vaccine within 4&#xD;
             weeks (except 2 weeks for flu vaccine)&#xD;
&#xD;
         11. Be currently pregnant or lactating, or anticipate getting pregnant within the one-year&#xD;
             study period.&#xD;
&#xD;
         12. Have severe obesity: adults BMI ≥ 40&#xD;
&#xD;
         13. Have a history of malignancies&#xD;
&#xD;
         14. Untreated hypothyroidism or active Graves' disease&#xD;
&#xD;
         15. History of severe reaction to prior vaccination&#xD;
&#xD;
         16. Participation in any clinical trial of an approved or non-approved investigational&#xD;
             medicinal product within 30 days after last blood draw (or 5 half-lives of&#xD;
             investigational drug, whichever is greater) before screening, or currently enrolled in&#xD;
             any other clinical trial&#xD;
&#xD;
         17. Subject is the investigator or any sub-investigator, research assistant, pharmacist,&#xD;
             study coordinator, other staff or relative thereof directly involved in the conduct of&#xD;
             the trial&#xD;
&#xD;
         18. Supine blood pressure at screening outside the range of 90-139 mmHg for systolic or&#xD;
             50-89 mmHg for diastolic. To exclude white-coat nervousness a single repeat&#xD;
             measurement is allowed&#xD;
&#xD;
         19. Have any complicating medical issues or abnormal clinical laboratory results that may&#xD;
             interfere with study conduct, or cause increased risk&#xD;
&#xD;
         20. Any condition that in the investigator's opinion may adversely affect study&#xD;
             participation or may compromise the study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Goland, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Type 1 Diabetes TrialNet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carla Greenbaum, MD</last_name>
    <role>Study Director</role>
    <affiliation>Type 1 Diabetes TrialNet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Rafkin, MS</last_name>
    <phone>305-243-6146</phone>
    <email>LRafkin@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryan O'Donnell, MS</last_name>
    <email>Ryan.O'Donnell@epi.usf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Speer</last_name>
      <phone>714-509-8613</phone>
      <email>HSpeer@choc.org</email>
    </contact>
    <investigator>
      <last_name>Mark Daniels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Wesch</last_name>
      <phone>415-476-5984</phone>
      <email>rebecca.wesch@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Ko</last_name>
      <phone>415-514-3730</phone>
      <email>karen.ko@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trudy Esrey</last_name>
      <phone>650-498-4450</phone>
      <email>tesrey@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Darrell Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center at University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Sooy</last_name>
      <phone>303-724-5686</phone>
      <email>MORGAN.QUIST@CUANSCHUTZ.EDU</email>
    </contact>
    <investigator>
      <last_name>Andrea Steck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Feldman</last_name>
      <phone>203-737-2760</phone>
      <email>laurie.feldman@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Kevan Herold, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hosford</last_name>
      <phone>352-294-5759</phone>
      <email>jennifer.hosford@peds.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Haller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Children's Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaomiao Lan-Pidhainy</last_name>
      <phone>404-712-0051</phone>
      <email>xlanpid@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Muir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University - Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Spall</last_name>
      <phone>317-278-8879</phone>
      <email>malnicho@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Linda DiMeglio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora Bryant</last_name>
      <phone>617-309-4141</phone>
      <email>nora.bryant@joslin.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Gaglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regents of the University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55466</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Leschyshyn</last_name>
      <phone>612-626-8467</phone>
      <email>lesch004@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Antoinette Moran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer James</last_name>
      <phone>913-696-5059</phone>
      <email>jljames@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Wayne Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Naomi Berrie Diabetes Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pollak</last_name>
      <phone>212-851-5425</phone>
      <email>sjp2174@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Robin Goland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelli DeLallo</last_name>
      <phone>412-692-5210</phone>
      <email>kelli.delallo@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Dorothy Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Eskind Diabetes Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faith Brendle</last_name>
      <phone>615-936-8638</phone>
      <email>faith.brendle@vumc.org</email>
    </contact>
    <investigator>
      <last_name>William Russell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serey Sao</last_name>
      <phone>214-648-3061</phone>
      <email>serey.sao@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Harter</last_name>
      <email>Lindsay.Harter@UTSouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Perrin White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinna Tordillos</last_name>
      <phone>206-341-8937</phone>
      <email>ctordillos@benaroyaresearch.org</email>
    </contact>
    <investigator>
      <last_name>Carla Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available at the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK) Central Repository</ipd_description>
    <ipd_url>https://repository.niddk.nih.gov/home/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

